Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic

BACKGROUND: Randomised trials of tamoxifen versus placebo indicate that tamoxifen reduces breast cancer risk by approximately 33%, yet uptake is low. Approximately 10% of women in our clinic entered the IBIS-I prevention trial. We assess the uptake of tamoxifen in a consecutive series of premenopaus...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Donnelly, L S, Evans, D G, Wiseman, J, Fox, J, Greenhalgh, R, Affen, J, Juraskova, I, Stavrinos, P, Dawe, S, Cuzick, J, Howell, A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2014
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3974072/
https://ncbi.nlm.nih.gov/pubmed/24594998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.109
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki